NCT05293834 Virtual Reality Aggression Prevention Training (VRAPT) for (Forensic) Psychiatric Patients
| NCT ID | NCT05293834 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Basel, Switzerland |
| Condition | Forensic Psychiatry |
| Study Type | INTERVENTIONAL |
| Enrollment | 68 participants |
| Start Date | 2022-09-21 |
| Primary Completion | 2027-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 68 participants in total. It began in 2022-09-21 with a primary completion date of 2027-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Violent and aggressive behavior as well as disorders related to aggressive behavior are highly common in both adult and juvenile forensic psychiatric patients, and is also present in a subgroup of non-forensic psychiatric in- and out-patients. One promising new treatment option is Virtual Reality. A newly developed program in this area is the Virtual Reality Aggression Prevention Training (VRAPT). The purpose of the current feasibility and pilot study is to test VRAPT in a Swiss forensic and non-forensic psychiatric setting, including both adult and juvenile patients, and to examine whether VRAPT is an effective treatment method for aggressive behavior.
Eligibility Criteria
Inclusion Criteria: * forensic and non-forensic psychiatric in- and out-patients of the Forensic Department or Adult Department of the Psychiatric University Hospitals Basel with aggressive behavior problems according to their clinical treatment team (which includes senior medical doctor, therapist, nursing staff). Exclusion Criteria: * insufficient German language skills (in speech or reading); * intellectual disabilities (IQ \< 70); * epilepsy; * acute psychotic state.
Contact & Investigator
Cyril Boonmann, PhD
PRINCIPAL INVESTIGATOR
Psychiatric University Hospitals (UPK) Basel
Frequently Asked Questions
Who can join the NCT05293834 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, studying Forensic Psychiatry. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05293834 currently recruiting?
Yes, NCT05293834 is actively recruiting participants. Contact the research team at cyril.boonmann@upk.ch for enrollment information.
Where is the NCT05293834 trial being conducted?
This trial is being conducted at Basel, Switzerland.
Who is sponsoring the NCT05293834 clinical trial?
NCT05293834 is sponsored by University Hospital, Basel, Switzerland. The principal investigator is Cyril Boonmann, PhD at Psychiatric University Hospitals (UPK) Basel. The trial plans to enroll 68 participants.